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Is hypnotherapy helpful for irritable bowel syndrome in 
primary and secondary care?
Gut-directed hypnotherapy has been investigated 
extensively over the past three decades as an 
intervention for irritable bowel syndrome (IBS) in 
adults. Almost 30 studies of clinical outcomes, including 
ten randomised controlled trials, have been published 
on the topic,1 with most showing that hypnotherapy 
significantly improved bowel symptoms and, often, 
the associated quality of life and emotional symptoms. 
On the basis of this body of research, multiple recent 
reviews1–4 have concluded that hypnotherapy is an 
effective treatment for IBS. 
However, an important limitation of the work to date 
is that most studies were done in tertiary-care centres, 
and many mainly or exclusively included patients who 
were unresponsive to conventional medical treatments 
for IBS. Therefore, the effectiveness of hypnotherapy for 
IBS in primary-care or secondary-care settings, where 
most patients with IBS are treated, is unclear.
In The Lancet Gastroenterology & Hepatology, 
Carla Flik and colleagues5 present the results of a 
large, randomised controlled trial that aimed to 
answer that question. With a sample size more than 
three times larger than any previous controlled trial of 
IBS hypnotherapy, and participation by clinicians in 
11 different hospitals in the Netherlands, the trial was of 
unprecedented scope in this research domain. 
The investigators randomly assigned 354 patients 
with IBS in primary and secondary care to one of three 
groups: individual hypnotherapy, group hypnotherapy, 
or an educational supportive control intervention 
carried out in groups. Participants in all three treatment 
arms received a total of six sessions, delivered every 
2 weeks, of their assigned intervention.  
The outcome of the trial was positive with regard to 
the primary endpoint, adequate relief of IBS symptoms. 
Patients in the two hypnotherapy treatment groups 
reported adequate relief at significantly higher rates 
than did those in the control group, immediately after 
the intervention and when reassessed 9 months later. 
That outcome would generally warrant the conclusion 
that hypnotherapy is helpful for treating patients 
with IBS in primary and secondary care. However, that 
conclusion seems doubtful in this instance, because 
none of the secondary outcome measures—which were 
well chosen and should have informed us of the exact 
benefits the patients derived from the intervention—
showed any advantage from hypnosis treatment. 
Bowel symptom severity, quality of life, psychological 
symptoms, health-care costs, and work disability 
showed no greater improvement in the hypnotherapy 
groups than in the control group. It is therefore hard 
to see that the health problem of IBS or its associated 
effects on emotional wellbeing and quality of life were 
specifically improved by hypnotherapy.
A second reason to question the efficacy of the 
therapy tested in this trial is that, even if adequate 
relief of symptoms is accepted as treatment success 
in the absence of any other evidence of therapeutic 
gains, the responder rate was unusually low: 40·8% in 
the individual therapy group and 33·2% in the group 
hypnotherapy group immediately after treatment. 
These success rates are at the bottom of the range 
compared with other studies1 on IBS hypnotherapy.
The reasons for the modest therapeutic effect in this 
study are uncertain, but there are a number of possible 
contributing factors. First, the hypnotherapy tested was 
a structured approach based on the Manchester group’s 
clinical protocol in the UK,6 which has been successfully 
applied with high (≥70%) success rates in several 
published IBS studies.7–10 However, the trial deviated 
notably from the Manchester approach by providing 
patients with only six therapy sessions instead of the 
Manchester group’s typical 12-session course. Second, 
as the authors note in their discussion, the therapy was 
delivered by psychologists who were not experienced in 
treating IBS, and IBS-related education was not provided 
to the patients receiving hypnosis, even though doing 
so is typical in the Manchester hypnotherapy approach. 
Thus, the hypnotherapy tested in this study might 
have been suboptimal in amount or implementation. 
However, as the authors note, the smaller therapeutic 
effect in this trial compared with most hypnotherapy 
trials in tertiary care might have been because IBS 
in primary and secondary care is different to that in 
tertiary care—perhaps simpler in nature and with less 
involvement of psychological factors. 
Therefore, despite this impressive investigative effort 
by Flik and colleagues, it remains unclear whether gut-
directed hypnotherapy is well suited for the treatment 
of patients with IBS in primary and secondary care, and 
future trials are needed to provide definitive answers.
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